PMID- 24431153
OWN - NLM
STAT- MEDLINE
DCOM- 20141103
LR  - 20220316
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 86
IP  - 5
DP  - 2014 May
TI  - Looking for biological factors to predict the risk of active cytomegalovirus 
      infection in non-immunosuppressed critically ill patients.
PG  - 827-33
LID - 10.1002/jmv.23838 [doi]
AB  - The identification of non-immunosuppressed critically ill patients most at risk 
      for developing cytomegalovirus (CMV) reactivation is potentially of great 
      clinical relevance. The current study was aimed at determining (i) whether single 
      nucleotide polymorphisms in the genes coding for chemokine receptor 5 (CCR5), 
      interleukin-10 IL-10), and monocyte chemoattractant protein-1 (MCP-1) have an 
      impact on the incidence rate of active CMV infection, (ii) whether serum levels 
      of CMV-specific IgGs are associated with the risk of CMV reactivation, and (iii) 
      whether detection of CMV DNA in saliva precedes that in the lower respiratory 
      tract or the blood compartment. A total of 36 out of 78 patients (46%) developed 
      an episode of active CMV infection. The incidence rate of active CMV infection 
      was not significantly associated with any single nucleotide polymorphisms. A 
      trend towards a lower incidence of active CMV infection (P = 0.06) was noted in 
      patients harboring the IL10 C/C genotype. Patients carrying the CCR5 A/A genotype 
      had high CMV DNA loads in tracheal aspirates. The serum levels of CMV IgGs did 
      not differ significantly between patients with a subsequent episode of active CMV 
      infection (median, 217 IU/mL) or without one (median, 494 IU/mL). Detection of 
      CMV DNA in saliva did not usually precede that in plasma and/or tracheal 
      aspirates. In summary, the analysis of single nucleotide polymorphisms in the 
      IL10 and CCR5 genes might help to determine the risk of active CMV infection or 
      the level of CMV replication within episodes, respectively, in 
      non-immunosuppressed critically ill patients.
CI  - (c) 2013 Wiley Periodicals, Inc.
FAU - Bravo, Dayana
AU  - Bravo D
AD  - Microbiology Service, Hospital Clinico Universitario, Institute for Research 
      INCLIVA, Valencia, Spain.
FAU - Clari, Maria A
AU  - Clari MA
FAU - Aguilar, Gerardo
AU  - Aguilar G
FAU - Belda, Javier
AU  - Belda J
FAU - Gimenez, Estela
AU  - Gimenez E
FAU - Carbonell, Jose A
AU  - Carbonell JA
FAU - Henao, Liliana
AU  - Henao L
FAU - Navarro, David
AU  - Navarro D
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20131105
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Antibodies, Viral)
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCR5 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (DNA, Viral)
RN  - 0 (IL10 protein, human)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, CCR5)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Viral/blood
MH  - Biomarkers/*analysis
MH  - Chemokine CCL2/genetics
MH  - Critical Illness
MH  - Cytomegalovirus/*physiology
MH  - Cytomegalovirus Infections/*diagnosis/*epidemiology
MH  - DNA, Viral/isolation & purification
MH  - *Disease Susceptibility
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Incidence
MH  - Interleukin-10/genetics
MH  - Male
MH  - Middle Aged
MH  - Plasma/virology
MH  - Polymorphism, Single Nucleotide
MH  - Receptors, CCR5/genetics
MH  - Saliva/virology
MH  - *Virus Activation
MH  - Young Adult
OTO - NOTNLM
OT  - CMV DNA load
OT  - Single nucleotide polymorphisms
OT  - active CMV infection
OT  - critically ill patients
OT  - cytomegalovirus
EDAT- 2014/01/17 06:00
MHDA- 2014/11/05 06:00
CRDT- 2014/01/17 06:00
PHST- 2013/10/06 00:00 [accepted]
PHST- 2014/01/17 06:00 [entrez]
PHST- 2014/01/17 06:00 [pubmed]
PHST- 2014/11/05 06:00 [medline]
AID - 10.1002/jmv.23838 [doi]
PST - ppublish
SO  - J Med Virol. 2014 May;86(5):827-33. doi: 10.1002/jmv.23838. Epub 2013 Nov 5.